Pfizer Stock News

Pfizer Inc. (NYSE:PFE) Q4 2021 Earnings Conference Call February 8, 2022 10:00 AM ET Company Participants Chris Stevo - Senior Vice President and Chief Investor Relations Officer Albert…

Stocks that traded heavily or had substantial price changes Tuesday: Pfizer, Chevron fall; Harley-Davidson, Chegg rise

CEO Albert Bourla says that Pfizer is still negotiating further vaccine sales for 2022.

Pfizer CEO Albert Bourla said he was optimistic that U.S regulators would be approving its COVID-19 vaccine for children under five years old.

Pfizer CEO Albert Bourla said he was optimistic that U.S regulators would be approving its COVID-19 vaccine for children under five years old.

The company had a record year in financials, but some investors are concerned about the biotech stock''s future.

Pfizer Quietly Adds Language Warning That ''Unfavorable Pre-Clinical, Clinical Or Safety Data'' May Impact Business Two weeks ago, the FDA begged a Texas judge to delay production on the first monthly batch of 55,000 pages of Covid-19 vaccine data submitted to the agency by Pfizer. Originally, the agency was set to produce just 500 pages-per-month. Now, Pfizer - which just forecast $54 billion in Covid-related sales in 2022, appears to be anticipating some bad news , as evidenced by several redline changes in their Q4 earnings releases. As Rubicon Capital''s Kelly Brown notes on Twitter, the changes center around disclosures of unfavorable safety data . For example, in Q4 they added: " or further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection ." More from Brown, who notes that Pfizer is now highlighting " concerns about clinical data integrity …" (2/3) "...challenges related to public confidence or awareness of our COVID-19 vaccine or Paxlovid, including challenges driven by misinformation, access, CONCERNS ABOUT CLINICAL DATA INTEGRITY and prescriber and pharmacy education;" (all-caps are mine) pic.twitter.com/bAKH4iqiKs — Kelly Brown (@rubiconcapital_) February 8, 2022 The company also notes that Covid-19 may "diminish in severity or prevalence, or disappear entirely." Links to Pfizer''s earnings releases referenced above: Q4: https://t.co/yCd1Ga8gPu Q3: https://t.co/CJ8k9oGQ1U — Kelly Brown (@rubiconcapital_) February 8, 2022 What''s behind the curtain, Pfizer?

Pfizer is expecting to have a record year in 2022, making up to $102 billion in revenue. Its COVID-19 products like its vaccine and newly approved Paxlovid will produce much of it.

US stocks remained mostly higher on Tuesday, while the S&P 500 traded lower by 0.1%. Midway through trading Tuesday, the Dow traded up 0.20% to 35,161.03 while the NASDAQ rose 0.14% to 14,035.14. The S&P, however, fell 0.10% to 4,479.38. Check out this: Apple And 3 Other Stocks Sold By Insiders Leading and Lagging Sectors Materials shares rose by 0.9% on Tuesday. Meanwhile, top gainers in the sector included Century Aluminum Company (NASDAQ: CENX ), up 13% and Alcoa Corporation (NYSE: AA ) up 12%. In trading on Tuesday, energy shares tumbled by 2.1%. Top Headline Pfizer Inc. (NYSE: PFE ) posted better-than-expected earnings for its fourth quarter, while sales missed estimates. Pfizer posted quarterly earnings of $1.08 per share, beating analysts’ estimates of $0.87 per share. The company’s quarterly sales came in at $23.80 billion, versus market expectations of $24.20 billion. Pfizer said it sees FY22 adjusted earnings of $6.35 to $6.55 per share. Equities Trading UP American Rebel Holdings, Inc. (NASDAQ: AREB ) shares shot up 43% to $3.1566 following uplisting to Nasdaq on Monday.

US stocks remained mostly higher on Tuesday, while the S&P 500 traded lower by 0.1%. Midway through trading Tuesday, the Dow traded up 0.20% to 35,161.03 while the NASDAQ rose 0.14% to 14,035.14. The S&P, however, fell 0.10% to 4,479.38. Check out this: Apple And 3 Other Stocks Sold By Insiders Leading and Lagging Sectors Materials shares rose by 0.9% on Tuesday. Meanwhile, top gainers in the sector included Century Aluminum Company (NASDAQ: CENX ), up 13% and Alcoa Corporation (NYSE: AA ) up 12%. In trading on Tuesday, energy shares tumbled by 2.1%. Top Headline Pfizer Inc. (NYSE: PFE ) posted better-than-expected earnings for its fourth quarter, while sales missed estimates. Pfizer posted quarterly earnings of $1.08 per share, beating analysts’ estimates of $0.87 per share. The company’s quarterly sales came in at $23.80 billion, versus market expectations of $24.20 billion. Pfizer said it sees FY22 adjusted earnings of $6.35 to $6.55 per share. Equities Trading UP American Rebel Holdings, Inc. (NASDAQ: AREB ) shares shot up 43% to $3.1566 following uplisting to Nasdaq on Monday.

Pfizer Inc. (NYSE: PFE) Q4 2021 earnings call dated Feb. 08, 2022 Presentation: Operator Good day, everyone, and welcome to Pfizers Fourth Quarter 2021 Earnings Conference Call. Todays call is [] The post Pfizer Inc. (PFE) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .

Pfizer Inc. (NYSE: PFE) Q4 2021 earnings call dated Feb. 08, 2022 Presentation: Operator Good day, everyone, and welcome to Pfizers Fourth Quarter 2021 Earnings Conference Call. Todays call is [] The post Pfizer Inc. (PFE) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .

US stocks initially edged lower as Treasury yields continue to climb higher and after a wrath of corporate headlines remind investors that their favorite COVID trades are over. When the world shut down, investors became big fans of Pfizer and Peloton shares, one company provided hope to protect the vulnerable and the other created a []

US stocks initially edged lower as Treasury yields continue to climb higher and after a wrath of corporate headlines remind investors that their favorite COVID trades are over. When the world shut down, investors became big fans of Pfizer and Peloton shares, one company provided hope to protect the vulnerable and the other created a []

Covid has made it clear: the likes of Pfizer, in thrall to shareholders, only really care about their huge profits Pfizer has had an exceptionally good pandemic. Today it announced that its Covid-19 vaccine brought in $37bn billion last year , making it easily the most lucrative medicine in any given year in history. That isn’t all. For a company that was until recently the least trusted company in the least trusted industrial sector in the United States, Covid-19 has been a PR coup. Pfizer has become a household name over the last 12 months. The company was toasted on nights out in Tel Aviv , and there are cocktails named after its vaccine in bars across the world. The US president referred to Pfizer’s chief executive, Albert Bourla, as a “ good friend ”, and the great man parked his jet next to Boris Johnson’s at last year’s G7 summit in Cornwall. Nick Dearden is director of Global Justice Now Continue reading…